Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial Meeting Abstract
| Authors: | Grünwald, V.; Keizman, D.; Bedke, J.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; Rha, S. Y.; Waddell, T.; Sabbatini, R.; Barthelemy, P.; Burgents, J. E.; Ren, M.; Brown, I.; Saal, H.; Choueiri, T. K.; Motzer, R. J. |
| Abstract Title: | Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454684700041 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.531 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 531 -- Source: Wos |
